Pituitary Tumor Diagnosis and Treatment

Pituitary tumours, or pituitary neuroendocrine tumours (PitNETs), encompass a spectrum of lesions arising from anterior pituitary cells that may secrete hormones or remain non-functioning. Clinically, patients present with symptoms of hormone excess—such as acromegaly, Cushing’s disease or hyperprolactinaemia—or with mass-effect manifestations including headaches and visual field defects. Diagnosis integrates endocrinological assays to assess hormone profiles, high-resolution magnetic resonance imaging to delineate tumour size and extension, and histopathology with immunohistochemistry to classify tumour lineage and proliferation index. The World Health Organization classification stratifies PitNETs by hormone expression, transcription factor lineage and proliferative markers (Ki-67, p53), guiding prognostication and follow-up strategies. First-line treatment depends on tumour subtype: medical therapy with dopamine agonists for prolactinomas and somatostatin analogues or growth hormone receptor antagonists for somatotroph adenomas; surgical resection via a transsphenoidal approach remains the cornerstone for non-functioning tumours or those refractory to medical therapy. Radiotherapy and stereotactic radiosurgery are reserved for residual or recurrent disease. Emerging approaches target molecular drivers and the tumour microenvironment, raising the prospect of precision therapies and immunomodulation in aggressive or atypical adenomas.

Research from Nature Portfolio

Recent studies have elucidated genetic drivers in corticotroph adenomas associated with Cushing’s disease, revealing recurrent mutations in the deubiquitinases USP48 and in the BRAF kinase. These mutations enhance the transcription of proopiomelanocortin, thereby contributing to hypercortisolism, and crucially identify BRAF V600E as a targetable lesion sensitive to specific inhibitors. This work lays the groundwork for future precision medicine trials in corticotroph tumours.
Advances in single-cell transcriptomics of the developing human pituitary have defined discrete progenitor states and lineage trajectories. Although chiefly developmental, this cellular atlas provides a normative reference to distinguish aberrant cell states in tumours, offering a framework for the identification of novel biomarkers and illuminating the cellular origins of diverse PitNET subtypes.

Pituitary Tumor Diagnosis and Treatment publication trend

The graph below shows the total number of articles in pituitary tumor diagnosis and treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Pituitary neuroendocrine tumour (PitNET): A tumour arising from pituitary hormone-producing cells, classified by hormone secretion and cell lineage.

Transsphenoidal surgery: A minimally invasive surgical technique accessing the pituitary gland via the sphenoid sinus.

Dopamine agonist: A class of drugs that activates dopamine receptors to suppress prolactin secretion in prolactinomas.

Proopiomelanocortin (POMC): A precursor polypeptide cleaved to produce adrenocorticotropin, overexpressed in corticotroph tumours.

Vemurafenib: A small-molecule inhibitor targeting BRAF V600E mutations, proposed for use in mutated corticotroph adenomas.

References

1. Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors. Genome Medicine (2024).
2. How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers (2020).
3. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary (2019).
4. Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism (2019).
5. Single-cell transcriptomics identifies divergent developmental lineage trajectories during human pituitary development. Nature Communications (2020).
6. Identification of recurrent USP48 and BRAF mutations in Cushing’s disease. Nature Communications (2018).